Recombinant activated factor VII in liver patients: A retrospective cohort study from Australia and New Zealand

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 3, 2010, Pages 207-215

  Flower, Oliver ^a   Phillips, Louise E ^b   Cameron, Peter ^b   Gunn, Kerry ^c   Dunkley, Scott ^a   Watts, Andrew ^a   Rajbhandari, Dorrilyn ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Coagulopathy; Liver disease; NovoSeven; Recombinant activated factor VII; RFVIIa

Indexed keywords

PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ANAPHYLAXIS; ARTICLE; AUSTRALIA; BLEEDING; CHILD PUGH SCORE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMOSTASIS; HUMAN; LIVER DISEASE; LIVER HEMORRHAGE; LIVER TRANSPLANTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOSIS; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AUSTRALIA; COHORT STUDIES; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NEW ZEALAND; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 77950208792     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283333589     Document Type: Article

References (79)

1. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124.
2. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19:163-176.
3. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27:373-384.
4. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7:408-413.
5. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9:119-128.
6. Negrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):S19-S24.
7. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93:1027-1035.
8. Ghorashian S, Hunt BJ. 'Off-license' use of recombinant activated factor VII. Blood Rev 2004; 18:245-259.
9. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-1331.
10. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 2003; 49:39-48.
11. Mathew P. The use of rFVIIa in nonhaemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost 2004; 92:738-746.
12. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104:3858-3864.
13. Uhlmann EJ, Eby CS. Recombinant activated factor VII for nonhemophiliac bleeding patients. Curr Opin Hematol 2004; 11:198-204.
14. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590-595.
15. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22:83-96.
16. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305:242-248.
17. Cordova C, Musca A, Violi F, Alessandri C, Vezza E. Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin. Scand J Haematol 1982; 29:235-240.
18. Cowan DH. Effect of alcoholism on hemostasis. Semin Hematol 1980; 17:137-147.
19. de Almeida AJ, Campos-de-Magalhaes M, Brandao-Mello CE, de Oliveira RV, Yoshida CF, Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to viral and host factors. Hepatogastroenterology 2007; 54:964-968.
20. Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line. Blood 1986; 67:64-70.
21. Federico A, Filippelli A, Falciani M, Tuccillo C, Tiso A, Floreani A. Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies. World J Gastroenterol 2007; 13:3677-3683.
22. Feistauer SM, Penner E, Mayr WR, Panzer S. Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997; 25:1343-1345.
23. Fimognari FL, De Santis A, Piccheri C, Moscatelli R, Gigliotti F, Vestri A. Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 2005; 146:238-243.
24. Green G, Thomson JM, Dymock IW, Poller L. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976; 34:427-439.
25. Hallen A, Nilsson IM. Coagulation studies in liver disease. Thromb Diath Haemorrh 1964; 11:51-63.
26. Hillenbrand P, Parbhoo SP, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974; 15:83-88.
27. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91:267-275.
28. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
29. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37:1267-1276.
30. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22:112-118.
31. Kelly DA, Tuddenham EG. Haemostatic problems in liver disease. Gut 1986; 27:339-349.
32. Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49:1645-1648.
33. Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992; 103:641-646.
34. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101:1382-1390.
35. Marra F, Riccardi D, Melani L, Spadoni S, Galli C, Fabrizio P, et al. Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation. J Hepatol 1998; 28:654-661.
36. Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 2000; 99:207-214.
37. Ordinas A, Maragall S, Castillo R, Nurden AT. A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver. Thromb Res 1978; 13:297-302.
38. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14 (Suppl D):60D-66D.
39. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100:1311-1316.
40. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12:7725-7736.
41. van Wersch JW, Russel MG, Lustermans FA. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis. Eur J Clin Chem Clin Biochem 1992; 30:275-279.
42. vanDeWater L, Carr JM, Aronson D, McDonagh J. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood 1986; 67:1468-1473.
43. Vardareli E, Saricam T, Demirustu C, Gulbas Z. Soluble P selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterology 2007; 54:466-469.
44. Watanabe M, Shiraishi K, Itakura M, Matsuzaki S. Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease. Alcohol Clin Exp Res 1998; 22 (3 Suppl):97S-102S.
45. Yang Y, Harvey SA, Gandhi CR. Kupffer cells are a major source of increased platelet activating factor in the CCl4-induced cirrhotic rat liver. J Hepatol 2003; 39:200-207.
46. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 2004; 53:877-883.
47. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741-748.
48. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
49. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002; 35:616-621.
50. Franchini M, Montagnana M, Targher G, Zaffanello M, Lippi G. The use of recombinant factor VIIa in liver diseases. Blood Coagul Fibrinolysis 2008; 19:341-348.
51. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123-1130.
52. Brown JB, Emerick KM, Brown DL, Whitington PF, Alonso EM. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37:268-272.
53. Carvalho A, Leitao J, Louro E, Maia R, Geraldes C, Ventura C, et al. Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients. Rev Esp Enferm Dig 2002; 94:280-285.
54. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 36:1081-1085.
55. Gibbs NM. The place of recombinant activated factor VII in liver transplantation. Int Anesthesiol Clin 2006; 44:99-110.
56. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71:402-405.
57. Hoffman R, Mahajana A, Agmon P, Baruch Y, Brenner B. Successful use of recombinant activated factor VII (Novoseven) in controlling severe intraabdominal bleeding after liver needle biopsy. Thromb Haemost 2002; 87:346-347.
58. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123:118-126.
59. Kalicinski P, Kaminski A, Drewniak T, Ismail H, Szymczak M, Markiewicz M, Lukasiewicz H. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31 (1-2):378-379.
60. Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86:1125-1126.
61. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102:269-275.
62. Meijer K, Hendriks HG, De Wolf JT, Klompmaker IJ, Lisman T, Hagenaars AA, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003; 14:169-174.
63. Niemann CU, Behrends M, Quan D, Eilers H, Gropper MA, Roberts JP, Hirose R. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transfus Med 2006; 16:93-100.
64. Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol 1999; 31:747-750.
65. Porte RJ, Caldwell SH. The role of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11:872-874.
66. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, Gomez-Parra M, Arguelles Arias F, Guerrero-Aznar MD, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004; 2:78-84.
67. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138-143.
68. Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191:245-249.
69. Surudo T, Wojcicki M, Milkiewicz P, Czuprynska M, Lubikowski J, Jarosz K, et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc 2003; 35:2323-2325.
70. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008; 38:156-165.
71. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-721.
72. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care 2006; 10:R120.
73. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007:CD005011.
74. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
75. Zimmerman JE, Wagner DP, Seneff MG, Becker RB, Sun X, Knaus WA. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 1996; 23:1393-1401.
76. Raschke RA, Curry SC, Rempe S, Gerkin R, Little E,Manch R, et al. Results of a protocol for the management of patients with fulminant liver failure. Crit Care Med 2008; 36:2244-2248.
77. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40:897-903.
78. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, Burroughs AK. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12:1049-1061.
79. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248:61-68.